DUX4 and facioscapulohumeral muscular dystrophy: These data support the repurposing of existing clinical p38 inhibitors as potential therapeutics for FSHD and interestingly, the treatment of xenografted mice [34] with Losmapimod, a well-known p38 inhibitor, resulted in dose-dependent decreases in mRNA levels for DUX4 and DUX4 target genes [33].